Sanofi (SNY) Stock
Key stats
- Market cap
- $116.04B
- Price / Earnings ratio
- 25.8x
- EPS (TTM)
- $1.88
- Volume
- Loading
- 52-week high
- $52.68
- 52-week low
- $39.07
- Dividend yield
- 3.65%
- Dividend amount (latest)
- $1.77
- EPS vs analyst estimate
- +6.3%Q3 FY25 · $1.70 vs $1.60
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with SNY
Recent news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SNY

Sanofi Q3 Earnings Call Highlights
Sanofi Q3 Earnings Call Highlights
SNY

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
SNY

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
SNY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 77.05
- MACD 12/26/9
- 1.82
- EMA 9 of MACD
- 1.22
- MACD histogram
- 0.60
- SMA 50
- $42.52
- Price above SMA 50
- EMA 50
- $43.40
- Price above EMA 50
- SMA 200
- $44.34
- Price above SMA 200
- EMA 200
- $44.61
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.59 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SNY

Sanofi Q3 Earnings Call Highlights
Sanofi Q3 Earnings Call Highlights
SNY

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
SNY

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
SNY

Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
SNY

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
SNY

RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today?
RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today?
SNY

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
SNY

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
SNY

As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
SNY
News tone: automated (AI) classification of the article's content, not a price prediction.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Belen Garijo Lopez M.D. | CEO & Director | 1960 |
| Mr. François-Xavier Roger | Executive VP & CFO | 1962 |
| Dr. Michael Quigley Ph.D. | Chief Scientific Officer & Head of Research | — |
| Mr. Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | 1974 |
| Ms. Jamie Haney | Executive VP & General Counsel | — |
| Mr. Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 1957 |
| Ms. Veronique Jaillet | Executive VP & Interim Chief People Officer | — |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | — |
| Mr. Erik Wallström | Head of Therapeutic Area - Neurology Development | — |
| Mr. Thomas Triomphe | Executive Vice President of Vaccines | 1974 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 77.05
- MACD 12/26/9
- 1.82
- EMA 9 of MACD
- 1.22
- MACD histogram
- 0.60
- SMA 50
- $42.52
- Price above SMA 50
- EMA 50
- $43.40
- Price above EMA 50
- SMA 200
- $44.34
- Price above SMA 200
- EMA 200
- $44.61
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.9 | +4.2 | ||||||||||
| 2022 | +2.6 | +1.6 | +0.5 | +0.1 | +0.4 | -6.0 | -2.6 | -16.1 | -5.9 | +10.3 | +5.5 | +5.6 |
| 2023 | +0.3 | -3.9 | +15.7 | -1.0 | -4.5 | +6.8 | -0.5 | +0.2 | +1.0 | -15.5 | +0.9 | +6.4 |
| 2024 | -0.2 | -1.2 | +2.8 | +1.9 | -2.0 | -1.5 | +4.5 | +8.9 | +0.2 | -7.7 | -9.0 | +0.6 |
| 2025 | +12.8 | +2.1 | -1.9 | +1.1 | -8.7 | -1.8 | -7.0 | +5.8 | -4.8 | +1.6 | -0.3 | -3.0 |
| 2026 | -2.5 | +2.9 | +1.1 | -2.4 | -5.2 | -0.7 | +3.5 | +3.3 | -7.1 | +9.0 | +6.3 |
Corporate actions
Upcoming
No upcoming corporate actions for SNY



